Acetylsalicylzuur (aspirine)

Lisa Marquez Kroeze en Margot van Dijk
Gepubliceerd op 14 januari 2022
Laatste update november 2023

Bij een verhoogd risico op pre-eclampsie is het advies om tussen week 12 en week 16 van de zwangerschap te starten met acetylsalicylzuur. Acetylsalicylzuur staat in de volksmond bekend als aspirine. Naast een verhoogd risico op pre-eclampsie, wordt in sommige regio’s het gebruik van aspirine ook geadviseerd als er in een vorige zwangerschap sprake was van groeivertraging bij de baby. Soms wordt Ascal voorgeschreven in plaats van aspirine.

Aspirinegebruik kan mogelijk de kans op ontstaan van pre-eclampsie of groeivertraging verkleinen. Waarom wordt er ‘mogelijk’ beschreven in de huidige richtlijn? Wat is het verschil tussen aspirine en Ascal? Hoe effectief is aspirine? Wat zijn voor- en nadelen van aspirinegebruik in de zwangerschap? In dit artikel besteden we aandacht aan de vragen rondom aspirine en pre-eclampsie en groeivertraging.

ACOG: The American College of Obstetricians and Gynecologists. (2018). Low-Dose Aspirin Use During Pregnancy. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/07/low-dose-aspirin-use-during-pregnancy

Apotheek.nl. Geraadpleegd op 1 januari 2022, van https://www.apotheek.nl/medicijnen/acetylsalicylzuur-als-antistollingsmiddel?product=acetylsalicylzuur-neuro#hartinfarct-(hartaanval)

Askie, L. M., Duley, L., Henderson-Smart, D. J., Stewart, L. A., & PARIS Collaborative Group (2007). Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet (London, England), 369(9575), 1791-1798. https://doi.org/10.1016/S0140-6736(07)60712-0 

AZM: Academisch Ziekenhuis Maastricht. (2009, maart). Pre-eclampsie en HELLP syndroom (zwangerschapsvergiftiging)https://centraal.mumc.nl/sites/central/files/23254-0309_pre-eclampsie_en_hellp_syndroom_zwangerschapsvergiftiging_927431_4.pdf

Bakketeig, L. S., Bjerkedal, T., & Hoffman, H. J. (1986). Small-for-gestational age births in successive pregnancy outcomes: results from a longitudinal study of births in Norway. Early human development, 14(3-4), 187-200. https://doi.org/10.1016/0378-3782(86)90180-5

Brouwers, L., Van der Meiden‐van Roest, A. J., Savelkoul, C., Vogelvang, T. E., Lely, A. T., Franx, A., & Van Rijn, B. B. (2018). Recurrence of pre‐eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta‐analysis. PMC. Published. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283049/

Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., Forest, J. C., & Giguère, Y. (2010). Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstetrics and gynecology, 116(2 Pt 1), 402-414. https://doi.org/10.1097/AOG.0b013e3181e9322a

Chaemsaithong, P., Cuenca-Gomez, D., Plana, M. N., Gil, M. M., & Poon, L. C. (2019). Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? Elsevierhttps://pubmed.ncbi.nlm.nih.gov/31494125/

Cormick, G., Pilar Betrán, A., Ciapponi, A., Hall, D. R., & Hofmeyr, G. J. (2016). Inter-pregnancy interval and risk of recurrent pre-eclampsia: systematic review and meta-analysis. PMC. Published. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950816/

Duley, L., Meher, S., Hunter, K. E., Seidler, A. L., Askie, L. M., Cochrane Pregnancy and Childbirth Group, Nottingham Health Science Partners, Birmingham Women's Hospital, & University of Sydney. (2019). Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Libraryhttps://doi.org/10.1002/14651858.CD004659.pub3

EFCNI. European Foundation For The Care Of Newborn Infants, Hellp Stichting, Kleine Kanjers, Vereniging van Ouders van Couvveusekinderen, Schlembach, D., Verlohren, S., Reiss, I., & De Wit, H. (2018, mei). Pre-eclampsiehttps://www.efcni.org/wp-content/uploads/2018/07/EFCNI_Preeclampsia_Factsheet_Dutch_web.pdf

Farmacotherapeutisch Kompas. Zorginstituut Nederland. (2021, 3 augustus). acetylsalicylzuur (als trombocytenaggregatieremmer). Geraadpleegd op 1 januari 2022, van https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/a/acetylsalicylzuur__als_trombocytenaggregatieremmer_#zwangerschap

Gyselaers, W. (2015). PRE-ECLAMPSIE. zol.be. Geraadpleegd op 16 november 2021, van https://www.zol.be/verloskunde/pre-eclampsie

Hastie, R., Tong, S., Wikström, A. K., Sandström, A., Hesselman, S., & Bergman, L. (2021). Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. American journal of obstetrics and gynecology, 224(1), 95.e1-95.e12.

KNOV. (2011). Hypertensie aandoeningen tijdens de zwangerschap, bevalling en kraamperiode. https://assets.knov.nl/p/557056/none/PDF%20Vakkennis/KNOV_Standaard_Hypertensie_versie2012.pdf

Leitich, H., Egarter, C., Husslein, P., Kaider, A., & Schemper, M. (1997). A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. British journal of obstetrics and gynaecology, 104(4), 450-459. https://doi.org/10.1111/j.1471-0528.1997.tb11497.x

Ludvigsson, J. F., Lu, D., Hammarström, L., Cnattingius, S., & Fang, F. (2018). Small for gestational age and risk of childhood mortality: A Swedish population study. PLoS medicine15(12), e1002717. https://doi.org/10.1371/journal.pmed.1002717

Man, R., Hodgetts Morton, V., Devani, P., & Morris, R. K. (2021). Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. European journal of obstetrics, gynecology, and reproductive biology, 262, 105-112. https://doi.org/10.1016/j.ejogrb.2021.05.017

Mather, A. R., Dom, A. M., & Thorburg, L. L. (2021). Low-dose aspirin in pregnancy: who? when? how much? and why?. Current opinion in obstetrics & gynecology, 33(2), 65-71. https://doi.org/10.1097/GCO.0000000000000694

McDonald, S. D., Best, C., & Lam, K. (2009). The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. Epub. Published. https://pubmed.ncbi.nlm.nih.gov/19681845/

Nijkamp, E., & Aarts, A. (2015). Hypertensieve aandoeningen in de zwangerschap. NTOG, 10. https://www.kennispoort-verloskunde.nl/wp-content/uploads/2016/02/NTOG_2015_10_Hypertensieve_aandoeningen_in_de_zwangerschap-2.pdf

NVOG. (2018). Richtlijn Hypertensieve aandoeningen in de zwangerschap. https://richtlijnendatabase.nl/richtlijn/hypertensieve_aandoeningen_in_de_zwangerschap/acetylsalicylzuur_pre-eclampsie_zwangerschap.html 

NVOG. (2019, oktober). NVOG-module 'Wat is de rol van acetylsalicylzuur, gestart ≤16 weken amenorroeduur, ter preventie van pre-eclampsie bij zwangere vrouwen?' https://www.nvog.nl/wp-content/uploads/2019/10/NVOG-module-Acetylsalicylzuur-okt-2019.pdf

NVOG. (2017). Richtlijn Foetale Groei Restrictie. https://www.nvog.nl/wp-content/uploads/2017/12/Foetate-groeirestricie-FGR-15-09-2017.pdf

Perined | Geboortegewichtcurven (2018). Perined.nl. Geraadpleegd op 4 januari 2022, van https://www.perined.nl/geboortegewichtcurven

Poon, L. C., Wright, D., Rolnik, D. L., Gonzalez-Vanegas, O., Persico, N., & Nicolaides, K. H. (2017). Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal Of Obstetrics And Gynecologyhttps://doi.org/10.1016/j.ajog.2017.07.038

RCOG. (2014). The Investigation and Management of the Small-for-Gestational-Age Fetus (2de editie). https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdf

Roberge, S., Sibai, B., McCaw-Binns, A., & Bujold, E. (2016). Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trialshttps://pubmed.ncbi.nlm.nih.gov/26906184/

Roberge, S., Sibai, B., McCaw-Binns, A., & Bujold, E. (2016). Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. American journal of perinatology, 33(8), 781-785. https://doi.org/10.1055/s-0036-1572495

Roberge, S., Nicolaides, K., Demers, S., Hyett, J., Chaillet, N., & Bujold, E. (2017). The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. American journal of obstetrics and gynecology, 216(2), 110-120.e6. https://doi.org/10.1016/j.ajog.2016.09.076

Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28. PMID: 28657417. https://pubmed.ncbi.nlm.nih.gov/28657417/

Turner, J. M., Robertson, N. T., Hartel, G., & Kumar, S. (2020). Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 55(2), 157-169. https://doi.org/10.1002/uog.20859

Voskamp, B. J., Kazemier, B. M., Ravelli, A. C., Schaaf, J., Mol, B. W., & Pajkrt, E. (2013). Recurrence of small-for-gestational-age pregnancy: analysis of first and subsequent singleton pregnancies in The Netherlands. American journal of obstetrics and gynecology, 208(5), 374.e1-374.e3746. https://doi.org/10.1016/j.ajog.2013.01.045

White, S. L., Yu, R., Craig, J. C., Polkinghorne, K. R., Atkins, R. C., & Chadban, S. J. (2011). Diagnostic Accuracy of Urine Dipsticks for Detection of Albuminuria in the General Community. American Journal of Kidney Diseases, 58(1), 19-28. https://doi.org/10.1053/j.ajkd.2010.12.026

Niet Ingeschreven

> Bevat

  • 9 Hoofdstukken

Reacties